CML: Mechanisms of disease initiation and progression

Leukemia and Lymphoma

Volumn 11, Issue s1, 1993, Pages 47-50

  Wetzler, Meir ^a   Talpaz, Moshe ^a   Estrov, Zeev ^a   Kurzrock, Razelle ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

BCR ABL; Initiation; Interleukin 1 beta; Leukemia myeloid chronic; Philadelphia chromosome; Progression

Indexed keywords

INTERLEUKIN 1BETA; PROTEIN P53;

BLAST CELL CRISIS; CHRONIC MYELOID LEUKEMIA; CONFERENCE PAPER; HEMATOPOIETIC STEM CELL; HUMAN; LEUKEMOGENESIS; ONCOGENE C MYC; ONCOGENE H RAS; PHILADELPHIA 1 CHROMOSOME; TUMOR GROWTH; TUMOR SUPPRESSOR GENE;

BLAST CRISIS; CYTOKINES; FUSION PROTEINS, BCR-ABL; GENE EXPRESSION REGULATION, LEUKEMIC; GENES, ABL; GENES, MYC; GENES, RAS; HUMAN; LEUKEMIA, MYELOID, AGGRESSIVE-PHASE; LEUKEMIA, MYELOID, CHRONIC; LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE; ONCOGENES;

EID: 0027181263     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428199309047863     Document Type: Article

References (30)

1. The molecular genetics of Philadelphia chromosome positive leukemias
2. The human cellular ABL gene product in the chronic myelogenous leukemia cell line K562 has an associated tyrosine protein kinase activity
3. Transformation of immature hematopoietic cells by the P210 BCR/ABL oncogene product of the Philadelphia chromosome
4. Selective transformation of primitive lymphoid cells by the BCR/ABL oncogene expressed in long-term lymphoid or myeloid cultures
5. Clonal lymphoid progenitor cell lines expressing the BCR/ABL oncogene retain full differentiative function
6. BCR/ABL protein
7. BCR-ABL oncogene renders myeloid cell line factor independent: potential autocrine mechanism in chronic myeloid leukemia
8. A BCR-v-ABL oncogene induces lymphomas in transgenic mice
9. Comparison of expression in hemopoietic cells by retroviral vectors carrying two genes
10. BCR-ABL, the hallmark of chronic myeloid leukaemia in man, induces multiple haemopoietic neoplasms in mice
11. Induction of a chronic myelogenous leukemia-like syndrome in mice with v-ABL and BCR/ABL
12. BCR/ABL gene of the Philadelphia chromosome
13. Selective inhibition of leukemia cell proliferation by BCR-ABL antisense oligodeoxynucleotides
14. c-abl has a sequence specific enhancer binding activity
15. Activation of tyrosine kinase and microfilament-binding functions of c-abl by bcr sequences in bcr/abl fusion proteins
16. Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia
17. 1-positive leukemia including chronic myelogenous leukemia
18. Analysis of breakpoints within the bcr gene and their correlation with the clinical course of Philadelphia-positive chronic myelogenous leukemia
19. Does the breakpoint within the major breakpoint cluster region (m-bcr) influence the duration of the chronic phase in chronic myeloid leukemia? An analytical comparison of current literature
20. Alterations in the p53 gene and the clonal evolution of the blast crisis of chronic myelocytic leukemia
21. Rearrangements in the p53 gene in Philadelphia chromosome positive chronic myelogenous leukemia
22. Abnormalities of the retinoblastoma gene in the pathogenesis of acute leukemia
23. Ras oncogene mutations are rare late stage events in chronic myelogenous leukemia
24. Rare occurrence of N-ras point mutations in Philadelphia chromosome positive chronic myeloid leukemia
25. Molecular characteristics of chronic myelogenous leukemia in blast crisis
26. BCR-ABL in chronic myelogenous leukemia may correlate with disease progression
27. Constitutive expression of interleukin-1 beta correlates with interferon-alpha resistance in chronic myelogenous leukemia
28. Alteration in bone marrow adherent layer growth factor expression: A novel mechanism of chronic myelogenous leukemia progression
29. Suppression of chronic myelogenous leukemia colony growth by interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptors: A novel application for inhibitors of IL-1 activity
30. Chronologic sequence in appearance of clinical and laboratory findings characteristic of chronic myelocytic leukemia